153
Participants
Start Date
March 30, 2018
Primary Completion Date
July 12, 2021
Study Completion Date
July 12, 2021
Vilaprisan (BAY1002670)
2mg, once daily, oral
Meitetsu Hospital, Nagoya
Kano's Clinic for Women, Nagoya
Kyoritsu Narashinodai Hospital, Funabashi
Aso Iizuka Hospital, Iizuka
Jusendo Geneal Hospital Yuasa Foundation, Kōriyama
Sato Hospital, Takasaki
Hashimoto Clinic, Sapporo
Yoshio Clinic, Sapporo
Asahi-Clinic., Takamatsu
Kurashiki Medical Clinic, Kurashiki
Medical Topia Soka Hospital, Sōka
Sei Womens Clinic, Bunkyo
St.Luke's International Hospital, Chuoku
Akazawa Clinic, Fuchū
Toranomon Womens Clinic, Minato
Akasakamitsuke Miyazaki Obstetrics and Gynecology Clinic, Minato
Yokokura Clinic, Minato-ku
Tokyo Women's Medical University Hospital, Shinjuku-ku
Kato Internal medicine and Gynecology Clinic, Fukui
Hamanomachi Hospital, Fukuoka
Medical corporation keizukai Chayamachi Ladies Clinic, Osaka
Medical Corporation Koshinkai Nomura Clinic Namba, Osaka
Izuma Clinic, Osaka
Shizuoka Saiseikai General Hospital, Shizuoka
Toyama Prefectural Central Hospital, Toyama
Lead Sponsor
Bayer
INDUSTRY